XJPX7776
Market cap70mUSD
Dec 24, Last price
402.00JPY
1D
-1.47%
1Q
-48.40%
Jan 2017
-25.00%
IPO
-73.20%
Name
CellSeed Inc
Chart & Performance
P/E
—
P/S
58.48
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
7.39%
Revenues
190m
+50.39%
Net income
-847m
L+11.43%
CFO
-779m
L+8.56%
Profile
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 190,134 50.39% | 126,427 -21.80% | 161,673 -18.95% | ||
Cost of revenue | 539,393 | 510,167 | 1,005,876 | ||
Unusual Expense (Income) | |||||
NOPBT | (349,259) | (383,740) | (844,203) | ||
NOPBT Margin | |||||
Operating Taxes | 950 | 950 | 3,800 | ||
Tax Rate | |||||
NOPAT | (350,209) | (384,690) | (848,003) | ||
Net income | (846,534) 11.43% | (759,680) -16.78% | (912,871) 16.46% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,819,700 | 880,765 | 396,885 | ||
BB yield | -23.35% | -25.06% | -12.54% | ||
| Debt | |||||
Debt current | 7,500 | 7,500 | 1,250 | ||
Long-term debt | 143,750 | 151,250 | 158,750 | ||
Deferred revenue | |||||
Other long-term liabilities | 33,728 | 33,637 | 33,547 | ||
Net debt | (2,031,830) | (1,032,938) | (878,674) | ||
| Cash flow | |||||
Cash from operating activities | (779,435) | (718,006) | (817,152) | ||
CAPEX | (21,632) | (15,590) | (91,002) | ||
Cash from investing activities | 56,315 | 61,728 | (110,439) | ||
Cash from financing activities | 1,814,201 | 881,814 | 396,885 | ||
FCF | (339,925) | (377,452) | (912,341) | ||
| Balance | |||||
Cash | 2,163,292 | 1,072,210 | 846,674 | ||
Long term investments | 19,788 | 119,478 | 192,000 | ||
Excess cash | 2,173,573 | 1,185,367 | 1,030,590 | ||
Stockholders' equity | 778,097 | 731,608 | (726,035) | ||
Invested Capital | 1,571,602 | 639,117 | 1,942,780 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 28,760 | 20,923 | 17,198 | ||
Price | 271.00 61.31% | 168.00 -8.70% | 184.00 -25.51% | ||
Market cap | 7,794,088 121.73% | 3,515,114 11.08% | 3,164,432 -9.61% | ||
EV | 5,762,258 | 2,482,176 | 2,285,758 | ||
EBITDA | (341,320) | (375,849) | (841,715) | ||
EV/EBITDA | |||||
Interest | 1,128 | 835 | 911 | ||
Interest/NOPBT | |||||